"I made you coffee."
"Thanks, dear."
"Are you okay?"
"Yeah, why?"
"I just wondered, is all."
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
"I made you coffee."
"Thanks, dear."
"Are you okay?"
"Yeah, why?"
"I just wondered, is all."
Uncertainty is bad for business, so in some respects the U.S. Supreme Court’s decision to uphold the the healthcare reform law yesterday morning carries a bit of a silver lining, despite the obvious negative that the excise tax on medical device makers will live on.
If you don’t believe me, ask Katherine Owen, Stryker Corp’s VP of strategy and investor relations, who said as much in an investor’s conference last week.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
The medical device industry’s bid to repeal the medical device tax took what might prove to be a mortal blow today when the U.S. Supreme Court ruled the Affordable Care Act constitutional, according to a Boston University law professor who’s amicus brief was cited in the court’s opinion.
"Today was not a great day for people who were hoping to repeal the device tax," Prof. Kevin Outterson told MassDevice.com. Justice Ruth Ginsburg cited a brief prepared by Outterson, his colleagues and students supporting the government’s position that the law is constitutional.
The U.S. Supreme Court’s decision to uphold the healthcare reform law – and therefore the medical device tax – could bode well for medical device companies over the long term, Wall Street analysts say.
Companies have already baked the impact of the 2.3% revenue tax into their assumptions, as have most med-tech investors, the analysts say. That likely means a short-term hit on The Street, as the upside of repeal evaporated this morning, but longer-term growth as 30 million to 40 million new patients gain health insurance.
The U.S. Supreme Court voted to uphold the the healthcare reform law this morning, meaning the medical device tax is likely to stand.
The Supremes’ decision comes as a shock to observers who’d predicted that they would rule the Patient Protection & Affordable Care Act’s mandate unconstitutional. Chief Justice John Roberts joined the high court’s liberal wing in deciding that the mandate, which requires the uninsured to purchase health insurance or pay a penalty, qualifies as a tax.
The U.S. Supreme Court voted to uphold the individual mandate provision of the healthcare reform law this morning.
The Supremes’ decision comes as a surprise to observers who’d predicted that they would rule the mandate unconsitutional. Chief justice John Roberts joined the high court’s liberal wing in deciding that the mandate, which requires the uninsured to purchase health insurance or pay a penalty, qualifies as a tax.
Stay tuned to MassDevice.com as we cover this breaking news.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
It seems like everyone whose anyone is betting on not only what the Supreme Court will decide about the constitutionality of the Patient Protection and Accountable Care Act, but when.
Everyone that is, except doctors.
That’s because most doctors I know suspect the announcement will be made on Friday of this week.
New details on Johnson & Johnson’s (NYSE:JNJ) marketing of its controversial transvaginal mesh implants are again in the spotlight as unsealed documents suggest that the healthcare giant sold the devices for an additional 9 months after the FDA deemed the products adulterated and asked J&J to pull them off the shelves.